Applications/Dilutions

Packaging, Storage & Formulations

Notes

This product is produced by and distributed for Abnova, a company based in Taiwan.

Alternate Names for FKBP12.6 RNAi

12.6 kDa FK506-binding protein

calstabin 2,12.6 kDa FKBP

EC 5.2.1.8

FK506 binding protein 1B, 12.6 kDa

FK506-binding protein 12.6

FK506-binding protein 1B (12.6 kD)

FK506-binding protein 1B

FKBP12.6

FKBP-12.6

FKBP12.6h-FKBP-12

FKBP1B

FKBP-1B

FKBP1L

FKBP9

Immunophilin FKBP12.6

OTK4

OTK4PPIase FKBP1B

peptidyl-prolyl cis-trans isomerase FKBP1B

PKBP1L

PPIase

rotamase

Background

Position of the Chimera RNAi. The related RNAi products listed were designed from different accesion number but sharing the same RNAi sequence. Chimera RNA interference (chimera RNAi) is process by which small interfering RNA/DNA chimera triggers the destruction of mRNA for the original gene. The discovery work, design, and application of chimera RNAi has been pioneered by Professor Kaoru Saigo and Dr. Kumiko Ui-Tei at the University of Tokyo. Chimera RNAi has many advantages over the conventional siRNAs. First, it has been demonstrated to have reliable knock-down for over 10,000 human genes. Because the human genome is composed of an intricate, genetic network, chimera RNAi's unique design has successfully obviated the off-target effects including microRNA-based influence. Another advantage of the chimera RNAi technology is its effectiveness at low concentrations (0.5nM to 5nM); only mRNA is destroyed so genomic genes are not affected. Finally, having both the sense and anti-sense strands consisting RNA/DNA chimera, it offers much greater compound stability for streamlining in vitro and in vivo assays and applications while minimizing interferon induction and other adverse reactions.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. RNAi are guaranteed for 3 months from date of receipt.